Gene therapy is an attractive therapy for hepatocarcinoma, and several approaches have been studied using murine leukemia virus-derived retroviruses. We compared gene transfer efficacy and transgene expression kinetics after transduction of hepatocarcinoma cell lines using enhanced green fluorescent protein (EGFP)-expressing murine leukemia virus-derived retroviral vectors and HIV-derived lentiviral vectors. First, we showed that both retroviral and lentiviral vectors efficiently transduce cycling hepatocarcinoma cell lines in vitro. However, after cell cycle arrest, transduction efficacy remained the same for lentiviral vectors but it decreased by 80% for retroviral vectors. Second, we studied EGFP expression kinetics using lentiviral vectors expressing EGFP under the control of cytomegalovirus (CMV) or phosphoglycerolkinase (PGK) promoter. We show that the CMV promoter allows a stronger EGFP expression than the PGK promoter. However, in contrast to PGK-driven EGFP expression, which persists up to 2 months after transduction, CMV-driven EGFP expression rapidly decreased with time. This phenomenon is due to promoter silencing, and EGFP expression can be restored in transduced cells by using transcription activators such as interleukin-6 or phorbol myristate acetate/ionomycin and, to a lesser extent, the demethylating agent 5Ј-azacytidine. Altogether, our results suggest that lentiviral vectors, which allow efficient transduction of hepatocarcinoma cell lines with a strong and a sustained expression according to the promoter used, are promising tools for gene therapy of hepatocarcinomas.
P rimary liver cancer is one of the most frequent cancers worldwide. Hepatocellular carcinoma (HCC), the most prevalent histological form, is usually associated with liver cirrhosis and/or chronic viral hepatitis. [1] [2] [3] [4] Therapy for this cancer remains difficult. Surgery, liver transplantation, or resection is hindered by a high frequency of relapse and cannot be proposed to most patients due to size or local extension of the tumor at the time of diagnosis. [5] [6] [7] [8] [9] [10] [11] For these patients, intraarterial chemoembolization or percutaneous ethanol injection have been proposed but have failed to show any survival benefit. 9, 12, 13 Therefore, it is of importance to develop new therapeutic approaches such as gene transfer strategies. Various approaches have been considered that may result in different patterns of gene expression. In addition to specific targeting to tumor cells, two main parameters have to be considered: intensity and duration of transgene expression leading to an efficient synthesis of the therapeutic protein. These parameters are important to consider in view of the proposed strategies. Thus, intensity of gene expression is likely to be more important than long-term expression in the so-called "suicide gene therapy" strategies, whereas a prolonged expression will be mandatory for antioncogenic apoptosis induction or immunostimulatory approaches.
Integration of the transgene into the genome of the target cells could allow these different strategies to be combined. Murine leukemia virus (MLV)-derived retroviral vectors have been found to efficiently transduce hepatoma-derived tumor cell lines, and encouraging results have been reported in the treatment of tumors implanted in nude mice. 14 -16 However, efficient transduction is limited to cycling cells. 17 HIV-1-derived lentiviral vectors have recently been developed. HIV-derived vectors share several advantages with MLVderived retroviral vectors, especially in terms of transgene integration into the cellular DNA, allowing a potential prolonged transgene expression. In addition, they are theoretically more efficient than retroviral vec-tors at transducing quiescent or slow-dividing cells such as HCC cells. 18 -20 Because gene transfer efficacy in HCC cells has not been fully documented for these two gene delivery approaches, this study was designed to compare the transduction efficiencies and the transgene expression kinetics after retroviral-or lentiviral-mediated gene transfer into human HCC cell lines.
MATERIALS AND METHODS

Cells
HeLa T cells and 293T cells were kindly provided by M. Vega (Genethon III, Evry, France). HuH7, Hep3B, and HepG2 cells were purchased from the American Type Culture Collection (Manassas, Va). Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, penicillin, and streptomycin.
Fluorescence-activated cell sorter (FACS) analysis
The percentage of enhanced green fluorescent protein (EGFP)-expressing cells and the fluorescence intensity were determined by FACS analysis. Briefly, cells were trypsinized and resuspended in DMEM (Life Technologies, Erangy, France). An aliquot of each cell culture was counterstained with propidium iodide and analyzed on a flux cytometer (Becton Dickinson, San Jose, Calif). The percentage of EGFPexpressing cells was determined by using a threshold establishing that Ͻ1% of nontransduced cells were considered as EGFP-expressing cells. The relative fluorescence intensity (RFI) was calculated as follows: RFI ϭ (TC MF Ϫ NTC MF)/NTC MF, where TC MF is the mean fluorescence intensity of the transduced cell population and NTC MF is the mean fluorescence intensity of the nontransduced cells.
Generation and production of retroviral and lentiviral vectors
The lentiviral vectors pHRCMV-EGFP and pHRPGK-EGFP (kindly provided by D. Trono, University of Geneva, Geneva, Switzerland) encode the EGFP placed under the control of the internal human cytomegalovirus (CMV) promoter or the phosphoglycerolkinase (PGK) gene promoter, respectively. 19, 20 Lentiviral particles, called LentiCMV-EGFP and LentiPGK-EGFP in this study, were generated by using a triple cotransfection procedure on 293T cells. 293T cells were transfected with pHRCMV-EGFP or pHRPGK-EGFP, with the vesicular stomatitis virus-G-encoding plasmid pMDG, and with the packaging plasmid p⌬R8.9 by using a polyethylenimine-mediated transfection procedure. 19, 20 The transfection efficacy was determined by FACS analysis and ranged from 80 to 90%. Transfected cells produced vesicular stomatitis virus-G-pseudotyped lentiviral vectors with titers ranging from 10 5 to 10 6 transducing units/mL. Supernatants were aliquoted and stored at Ϫ80°C until use.
The pSF␤ MLV retroviral backbone was a kind gift of C. Baum 21 and was engineered to encode the EGFP by inserting the NcoI-blunted StatI fragment encoding the EGFP cDNA from the pEGFP1 plasmid between the NcoI and the blunted BamHI sites in the pSF␤ backbone. In this vector, the EGFP gene is placed under the control of the spleen focus-forming virus (SF) 5Ј-long terminal repeat promoter. Vector particles, called RetroEGFP in this study, were derived from Phoenix-EGFP, an amphotropic packaging Phoenix cell line (kindly provided by G. Nolan, Stanford University Stanford, Calif) stably transduced with the SF-EGFP retroviral vector. Producer cells (Phoenix SF-EGFP) were seeded into culture dishes at a density of 5 ϫ 10 4 cells/cm 2 . Once cells were adherent, culture medium was replaced with fresh medium. Vector supernatants were harvested 24 hours later, cleared of cellular debris by filtration through 0.45-m nitrocellulose filters (Nalgene, Rochester, NY), aliquoted, and stored at Ϫ80°C. All supernatants were free of helper virus as determined by replication-competent retrovirus test.
Titration of lentiviral and retroviral vector supernatants was performed on HeLa T cells and Rat2 cells, respectively, as described previously. 22 Briefly, 10 5 cells/well were plated in 12-well dishes. After 1 day, the cells were transduced in 500 L of culture medium containing 4 g/mL polybrene. The transduction medium was removed 16 hours later and the cells were grown in 10% fetal calf serum/DMEM for 3 days. At least three different dilutions were examined for each viral preparation. The percentage of transduced cells was determined by FACS analysis, and the viral titer was calculated as described previously. 22 
Transduction of hepatoma cells
On day 0, 10 5 cells/well were seeded in 12-well dishes. On day 1, the medium was removed and replaced with 500 L of fresh transduction medium supplemented with 4 g/mL polybrene and 10 -150 L of nonconcentrated viral supernatant. Cells were incubated for 16 hours. Next, the transduction medium was removed and replaced with fresh medium. The percentage of EGFP-expressing cells and the fluorescence intensity were determined by FACS analysis on days 3, 15, 30, 45, and 60 posttransduction.
Transduction of growth-arrested hepatoma cells
On day 0, 10 5 HuH7 and Hep3B cells/well were seeded in 12-well plates. On day 1, the cells were treated for 3 hours with 20 g/mL mitomycin-C (MMC). Cells were then transduced with LentiPGK-EGFP or RetroEGFP at three different multiplicities of infection (MOIs) in the presence of 4 g/mL polybrene in a volume of 500 L as described above. Control cells included transduced cells without MMC treatment and MMC-treated nontransduced cells. At 3 days posttransduction, EGFP expression was monitored by FACS. At least three different experiments were performed for each cell line studied.
Transduction efficacy according to the duration of exposure to the viral preparation On day 0, 10 5 hepatocarcinoma cells/well were seeded in 12-well plates. Cells were transduced on day 1 with LentiPGK-EGFP (MOI of 1.5) in the presence of 4 g/mL polybrene. We used five different periods of exposure to the viral preparation: 5 minutes, 15 minutes, 1 hour, 4 hours, and 16 hours. After transduction, cells were washed twice with fresh medium. The percentage of EGFP-expressing cells was measured by FACS analysis on day 3 posttransduction. Three independent experiments were performed for each period of exposure.
EGFP expression stimulation assays
EGFP stimulation was monitored 60 days after LentiCMV-EGFP transduction. In an initial set of experiments, cells were incubated for 24 hours in a medium containing 2 g/mL ionomycin (iono) and 20 ng/mL phorbol myristate acetate (PMA) or in a medium supplemented with interleukin-6 (IL-6) (1000 IU/mL) and dexamethasone (100 nM). In a second set of experiments, cells were incubated in a medium containing 5-azacytidine (5-aza) (4 M) for 48 hours and then stimulated with either PMA/iono or IL-6/dexamethasone for 24 hours. The percentage of EGFP ϩ cells was determined by FACS at the end of the stimulation period. Control cells included nontransduced cells incubated in a different stimulating medium and transduced cells incubated without stimulators. At least three independent experiments were performed for each set of experiments.
RESULTS
Transduction efficacy of hepatoma cell lines HuH7, Hep3B, and HepG2 cells were plated in 12-well dishes and transduced with retroviral or lentiviral constructs at MOIs of 0.1, 0.5, 1, and 1.5. The percentage of EGFP-expressing cells was determined by FACS on day 3 posttransduction. The results obtained with LentiCMV-EGFP, LentiPGK-EGFP, and RetroEGFP are presented in Figure 1 . Both lentiviral vectors very efficiently transduced the three different cell lines in a dose-dependent manner. Indeed, at an MOI of 1, Ͼ80% of the cells were transduced with LentiPGK-EGFP and ϳ75% of the cells were transduced with LentiCMV-EGFP as assessed by detection of EGFP expression (Fig   1, A-C) . Retroviral-mediated transduction efficacy was comparable with the results obtained with lentiviral constructs on HuH7 and HepG2 cells but was lower on Hep3B cells. In Hep3B cells, transduction efficacy reached only 50% of the cells after transduction with RetroEGFP at an MOI of 1.5, while it was close to 90% with both LentiCMV-EGFP and LentiPGK-EGFP ( Fig  1C) . This result may be related to the slower dividing rate of Hep3B cells compared with HuH7 and HepG2 cells. Indeed, in our hands the doubling time of HuH7 and HepG2 cells was 24 hours, while it was 36 hours for Hep3B cells.
Maximal fluorescence intensity on day 3 posttransduction was observed with LentiCMV-EGFP for the three cell lines studied. For HuH7, the RFI on day 3 posttransduction was ϳ5-fold higher after LentiCMV-EGFP transduction than after LentiPGK-EGFP transduction and 2.5-fold higher than after RetroEGFP transduction (Fig 2A) .
Transduction efficacy on growth-arrested cells HuH7 and Hep3B cells were incubated in a medium supplemented with MMC for 3 hours before transduction. MMC-treated cells and control cells not treated with MMC were transduced with LentiPGK-EGFP or RetroEGFP. When using RetroEGFP to transduce MMC-treated cells, the percentage of EGFP ϩ cells was decreased by Ͼ80% compared with control cells. After LentiPGK-EGFP transduction, the percentage of HuH7 cells expressing EGFP was identical with or without MMC treatment (Fig 1D) . For Hep3B cells, the percentage of EGFP-expressing cells was even higher for MMCtreated cells than for control cells. Altogether, lentiviral vectors efficiently transduced both dividing and nondividing hepatocarcinoma cells, whereas MLV-derived retroviral vector was clearly inefficient to transduce nondividing hepatocarcinoma cells.
Transduction efficacy according to duration of exposure to viral preparation An important point is that the in vivo the time of exposure to the viral preparation may be shorter than that usually used for in vitro experiments (i.e., 16 hours). It was therefore of interest to determine the minimal time of exposure to the viral preparation allowing an efficient gene transfer. We transduced HuH7 cells with LentiPGK-EGFP (MOI of 1.5) for 5 minutes, 15 minutes, 1 hour, 4 hours, or 16 hours. On day 3 posttransduction, the percentage of EGFP-expressing cells, for each duration of transduction, was 10.8 Ϯ 2, 29.9 Ϯ 1, 64.4 Ϯ 3, 84.6 Ϯ 2, and 94.5 Ϯ 2, respectively. Thus, gene transfer efficacy by using HIV-derived lentiviral vectors was clearly dependent upon the duration of transduction. However, a relatively short duration of transduction (i.e., 1 hour) was sufficient to achieve 70% gene transfer efficacy compared with the 16-hour transduction period.
Long-term expression of EGFP For long-term expression assay, the transduced cells were continuously propagated without selection. The percentage of EGFP-expressing cells and the RFI were determined on days 3, 15, 30, 45, and 60 posttransduction by FACS analysis (Fig 2) . When transduced with LentiCMV-EGFP, the percentage of EGFP-expressing cells progressively decreased. As early as 15 days posttransduction, the percentage of EGFP ϩ cells was decreased by 18, 30, and 35% for HuH7, HepG2, and Hep3B cells, respectively. On day 30 posttransduction, the overall decrease in the percentage of EGFP-expressing cells reached 70% for the three cell lines. Thus, at an MOI of 1, although Ͼ70% of the cells were found to be EGFP ϩ on day 3, only 25, 28, and 32% remained positive on day 30 for HuH7, HepG2, and Hep3B, respectively (Fig 2B) . The evolution of the RFI showed that maximal intensity was observed on day 3 posttransduction. But on day 15, the RFI was ϳ5-fold lower than on day 3 and still regularly decreased in the following days in the three cell lines studied (Fig 2A) .
Long-term expression of cells transduced with LentiPGK-EGFP exhibited a markedly different pattern. The percentage of EGFP-expressing cells was shown to be much more stable with time compared with LentiCMV-EGFP-transduced cells. Indeed, none of the cell lines studied exhibited a significant decrease in the percentage of EGFP-expressing cells up to 2 months posttransduction. After LentiPGK-EGFP transduction, the RFI on day 3 was significantly lower than after LentiCMV-EGFP transduction in the three cell lines studied. However, after LentiPGK-EGFP transduction, the RFI still increased after day 3 and was found to be 2-fold higher on day 15 compared with the RFI observed after LentiCMV-EGFP transduction for the three cell lines studied. EGFP expression remained stable up to 2 months after LentiPGK-EGFP transduction (Fig 2A) .
After RetroEGFP transduction, the percentage of EGFP-expressing cells remained stable in the three cell lines studied up to 60 days posttransduction. The maximal RFI was reached at 3 days posttransduction and was in the same range as the RFI observed after LentiPGK-EGFP transduction (Fig 2, A and B) .
Stimulation of EGFP expression
Assuming that silencing of the transferred promoter can be of importance in the observed decrease of the transgene expression, we incubated transduced cells from the three different cell lines with 5Ј-azacytidine (5-aza), a demethylating agent, or IL-6 and PMA/iono, used as transcription activators. The percentage of EGFP-expressing cells as well as the fluorescence index were expressed as a percentage of the values observed on day 3 after LentiCMV-EGFP transduction.
Incubation of LentiCMV-EGFP-transduced cells with PMA/iono, IL-6, and 5-aza restored, respectively, 90 Ϯ 19, 83 Ϯ 13, and 69 Ϯ 27% of EGFP-expressing cells (Fig 3) . PMA/iono induced a significantly higher EGFP re-expression than 5-aza (mean 90% vs. 69%, P Ͻ .05).
IL-6 induced a higher EGFP re-expression than 5-aza in HepG2 and Hep3B cells (mean 83% vs. 53%, P Ͻ .01) but lower re-expression in HuH7 cells. There was no significant difference in EGFP re-expression after PMA/ iono or IL-6 stimulation.
We subsequently combined 5-aza treatment and PMA/iono or IL-6/dexamethasone stimulation. This combination allowed a stronger increase in EGFP expression as well as RFI than each stimulator alone in the three cell lines studied. The mean percentage of EGFPexpressing cells after costimulation even reached 122% of the mean percentage of EGFP-expressing cells observed on day 3 posttransduction. Altogether, costimulation induced a significantly higher EGFP re-expression than each stimulator alone (P Ͻ .01) (Fig 3) .
DISCUSSION
In this work, we show that HIV-derived lentiviral vectors are more efficient than MLV-derived retroviral vectors at transducing hepatoma cells in vitro. The use of the EGFP marker gene allowed us to accurately compare transduction efficacy after retrovirus-or lentivirus-mediated gene transfer by FACS analysis. With this approach, it is possible to evaluate cell-by-cell EGFP expression and thus to determine both the percentage of EGFP-expressing cells after transduction and the fluorescence intensity of the transduced cells.
First, our results show that HIV lentiviral vectors are very efficient at transducing HCC cell lines, with ϳ70 -80% of EGFP-expressing cells after transduction with an MOI of 1. Lentiviral vectors were always at least as efficient as retroviral vectors in the three cell lines studied. Moreover, lentiviral vectors allowed very efficient transduction of nondividing hepatoma cells, whereas the transduction efficacy observed with retroviral vectors on these cells was decreased by Ͼ80%. This point is of major importance in view of the low cellular dividing rate usually observed in human primary liver tumors, suggesting HIV-derived vectors should be more efficient than retroviral vectors in vivo. Moreover, gene therapy protocols will probably be combined with other therapeutical approaches such as surgery or intra-arterial chemotherapy. In this view, it is noteworthy that MMC is frequently used in chemotherapy protocols for HCC treatment. 9 -12 Our results suggest that MMCbased chemotherapy could be administered without affecting lentiviral-mediated gene transfer efficacy to tumor cells, whereas it would dramatically reduce retroviral-mediated gene transfer to HCCs. Most HCCs develop in a context of chronic hepatitis B virus (HBV) or hepatitis C virus infection. No data are available on retroviral-or lentiviral-mediated gene transfer efficacy in cells infected with these viruses. However, it is interesting to note that lentiviral vectors transduced the three human HCC cell lines very efficiently, including Hep3B cells that are derived from a tumor developed in the context of HBV infection because they contain HBV DNA sequences. This suggests that HIV-derived lenti- Second, we evaluated the role of two promoters, CMV and PGK, on EGFP expression kinetics. We show that the LentiCMV-EGFP construct allowed the highest EGFP expression on day 3 posttransduction, with an RFI that was ϳ5-fold higher than the RFI observed on day 3 after LentiPGK-EGFP transduction. However, after LentiCMV-EGFP transduction, we observed a dramatic decrease in EGFP expression with time. Decrease in transgene expression after retroviral-mediated gene transfer due to DNA hypermethylation is a wellknown phenomenon. 23 5-aza is a demethylating agent that has been shown to prevent DNA methylation in vitro and in vivo and to allow transgene re-expression once DNA methylation has occurred. 23, 24 We showed that 5-aza treatment partially restored EGFP expression, indicating that DNA methylation should be involved in the decrease of EGFP expression observed after LentiCMV-EGFP transduction. However, transcription stimulators acting via the nuclear factor-B-dependent pathway (PMA/iono) 25, 26 or nuclear factor-B-independent pathway (IL-6/ dexamethasone) 27 induced a more powerful EGFP expression than 5-aza, suggesting that CMV promoter-silencing mechanisms other than hypermethylation of DNA also are involved in the decrease of LentiCMV-EGFP-driven EGFP expression. 27 The particularly strong EGFP expression observed after costimulation with both 5-aza and transcription stimulators favors this hypothesis. It is of note that the same phenomenon of CMV promoter silencing has been described previously after adenoviral, adeno-associated viral, and retroviral vector-mediated gene transfer in liver cells and some other cell types, 28 -31 suggesting it is a specific feature of the CMV promoter independent of the lentiviral vector gene strategy.
Altogether, our results suggest that the CMV promoter allows a strong transgene expression; however, after a short period of time, this promoter behaves like an inducible rather than a constitutive strong promoter. Therefore, the CMV promoter would be of interest for gene therapy strategies such as the so-called suicide gene therapy in which strong expression of the transgene is mandatory. Conversely, if a sustained transgene expression is necessary, the PGK promoter should be more suitable.
In conclusion, assuming careful choice of the promoter is made, HIV-derived lentiviral vectors are promising tools to achieve efficient gene transfer in HCCs. They are able to transduce HCC cells very efficiently and allow a strong and a sustained expression of the transgene according to the promoter used. Further in vivo studies are necessary to confirm the interest of lentiviralmediated gene transfer for the treatment of HCCs.
